HLS Therapeutics (TSX:HLS) Interest Expense: C$-8.09 Mil (TTM As of Mar. 2026)

What is HLS Therapeutics Interest Expense?

HLS Therapeutics TSX:HLS +3.52% 62 Interest Expense is C$-8.09 Mil as of Mar. 2026. GuruFocus rates TSX:HLS with a GF Score™ of 62/100 and a GF Value™ of C$4.47 (Fairly Valued). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. HLS Therapeutics's interest expense for the three months ended in Mar. 2026 was C$ -1.10 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was C$-8.09 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. HLS Therapeutics's Operating Income for the three months ended in Mar. 2026 was C$ -3.04 Mil. HLS Therapeutics's Interest Expense for the three months ended in Mar. 2026 was C$ -1.10 Mil. HLS Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

HLS Therapeutics (TSX:HLS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

HLS Therapeutics's Interest Expense for the three months ended in Mar. 2026 was C$-1.10 Mil. Its Operating Income for the three months ended in Mar. 2026 was C$-3.04 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was C$53.80 Mil.

HLS Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

HLS Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

HLS Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for HLS Therapeutics's Interest Expense can be seen below:

HLS Therapeutics Interest Expense Chart

HLS Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-8.90

-9.94

-11.74

-14.37

-9.79

HLS Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-2.90	-2.37	-3.38	-1.24	-1.10

62GF Score

HLS Therapeutics Inc TSX:HLS

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

HLS Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-8.09 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of C$-8.09 Mil mean?

HLS Therapeutics (TSX:HLS) has a Interest Expense of C$-8.09 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on HLS Therapeutics and its competitors.

Is HLS Therapeutics' Interest Expense too high?

HLS Therapeutics' current Interest Expense is C$-8.09 Mil. Overall, HLS Therapeutics has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does HLS Therapeutics' Interest Expense compare to ZTS and UTHR?

HLS Therapeutics' Interest Expense of C$-8.09 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Drug Manufacturers company?

A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on HLS Therapeutics and its competitors. HLS Therapeutics's current Interest Expense is C$-8.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is HLS Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.47, compared to a current price of C$4.41 — trading 1.3% below its estimated fair value. The current Interest Expense is C$-8.09 Mil. HLS Therapeutics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Interest Expense is C$-8.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$4.41 is trading 1.3% below its estimated GF Value™ of C$4.47. GuruFocus considers HLS Therapeutics to be Fairly Valued.

Key valuation signals for TSX:HLS:

Interest Expense: C$-8.09 Mil
GF Value™: C$4.47 vs. price of C$4.41 (1.3% below fair value)
GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HLS Therapeutics Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TSX:MDP XCNQ:JUSH TSX:CWEB XCNQ:AAWH.U XCNQ:GRIN XCNQ:NVRS TSXV:RX TSX:LOVE TSX:CRDL TSXV:DB XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges HLTRF:USA 74D:Germany

Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2

Website https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.

62GF Score

Get the complete analysis for TSX:HLS

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$4.41

Price

C$4.47

GF Value

View TSX:HLS Analysis

See Interest Expense data for all stocks →